PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference
PepGen (Nasdaq: PEPG), a clinical-stage biotechnology company focused on developing next-generation oligonucleotide therapies for severe neuromuscular and neurological diseases, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's President and CEO, James McArthur, PhD, will deliver a corporate presentation on Wednesday, April 9, 2025, at 1:30pm ET. Investors and interested parties can access the webcast through PepGen's website investor section, and a replay will remain available for 90 days after the presentation.
PepGen (Nasdaq: PEPG), una compagnia biotecnologica in fase clinica focalizzata sullo sviluppo di terapie a base di oligonucleotidi di nuova generazione per malattie neuromuscolari e neurologiche gravi, ha annunciato la sua partecipazione alla 24ª Conferenza Virtuale Annuale di Needham sulla Salute.
Il Presidente e CEO dell'azienda, James McArthur, PhD, presenterà un intervento aziendale mercoledì 9 aprile 2025, alle 13:30 ET. Gli investitori e le parti interessate possono accedere al webcast attraverso la sezione investitori del sito web di PepGen, e una registrazione sarà disponibile per 90 giorni dopo la presentazione.
PepGen (Nasdaq: PEPG), una empresa biotecnológica en etapa clínica centrada en el desarrollo de terapias de oligonucleótidos de nueva generación para enfermedades neuromusculares y neurológicas severas, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Salud de Needham.
El Presidente y CEO de la compañía, James McArthur, PhD, realizará una presentación corporativa el miércoles 9 de abril de 2025, a la 1:30 p.m. ET. Los inversores y partes interesadas pueden acceder a la transmisión web a través de la sección de inversores del sitio web de PepGen, y una grabación estará disponible durante 90 días después de la presentación.
PepGen (Nasdaq: PEPG)는 중증 신경근육 및 신경 질환을 위한 차세대 올리고뉴클레오타이드 치료제를 개발하는 임상 단계의 생명공학 회사로, 제24회 연례 니드햄 가상 의료 회의에 참여한다고 발표했습니다.
회사의 회장 겸 CEO인 James McArthur, PhD는 2025년 4월 9일 수요일 오후 1시 30분 ET에 기업 발표를 진행할 예정입니다. 투자자 및 관심 있는 분들은 PepGen 웹사이트의 투자자 섹션을 통해 웹캐스트에 접근할 수 있으며, 발표 후 90일 동안 재생이 가능할 것입니다.
PepGen (Nasdaq: PEPG), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies par oligonucleotide de nouvelle génération pour des maladies neuromusculaires et neurologiques sévères, a annoncé sa participation à la 24e Conférence Virtuelle Annuelle de Needham sur la Santé.
Le Président et CEO de l'entreprise, James McArthur, PhD, fera une présentation d'entreprise le mercredi 9 avril 2025, à 13h30 ET. Les investisseurs et les parties intéressées peuvent accéder au webinaire via la section investisseurs du site Web de PepGen, et un enregistrement sera disponible pendant 90 jours après la présentation.
PepGen (Nasdaq: PEPG), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Oligonukleotidtherapien der nächsten Generation für schwere neuromuskuläre und neurologische Erkrankungen konzentriert, hat seine Teilnahme an der 24. jährlichen Needham virtuellen Gesundheitskonferenz angekündigt.
Der Präsident und CEO des Unternehmens, James McArthur, PhD, wird am Mittwoch, den 9. April 2025, um 13:30 Uhr ET eine Unternehmenspräsentation halten. Investoren und Interessierte können über den Investorenbereich der Website von PepGen auf das Webcast zugreifen, und eine Aufzeichnung wird 90 Tage nach der Präsentation verfügbar sein.
- None.
- None.
A webcast of the corporate presentation will be available on the "Events & Presentations" page within the Investors section of the PepGen website at https://investors.pepgen.com/. A replay of the webcast will be available on the PepGen website for 90 days following the presentation date.
About PepGen
PepGen is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.
For more information, please visit PepGen.com. Follow PepGen on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402335527/en/
Investor Contact
Dave Borah, CFA
SVP, Investor Relations and Corporate Communications
dborah@pepgen.com
Media Contact
Julia Deutsch
Lyra Strategic Advisory
Jdeutsch@lyraadvisory.com
Source: PepGen Inc.
FAQ
When is PepGen (PEPG) presenting at the Needham Healthcare Conference 2025?
How long will PepGen's (PEPG) Needham Conference presentation replay be available?
Where can investors access PepGen's (PEPG) Needham Conference presentation?
What type of therapies is PepGen (PEPG) developing?
